Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment.

ABSTRACT: Human papillomavirus (HPV) drives a substantial cancer burden across all genders. This perspective argues that gender-neutral HPV vaccination is an equitable and cost-effective public health investment when designed for scale. Rather than presenting methods in detail, we synthesize recent epidemiology, policy positions, and economic evaluations to propose a simplicity-first pathway-a pragmatic model that, where permitted, prioritizes single-dose schedules, school-based delivery for adolescents aged 9-14, small, computable set of key performance indicators (KPIs) set (coverage, timeliness, series completion, and equity gaps), routine adverse events following immunization (AEFI) monitoring, and phased expansion as system capacity grows. The simplicity-first pathway advances global equity by

SUBMITTER: Luo Q 

PROVIDER: S-EPMC12813166 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature